Liver cancer drug combo shows different results in different organs
NCT ID NCT04862949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a combination of two drugs (atezolizumab and bevacizumab) works on liver cancer tumors in different parts of the body. Researchers wanted to see if the drugs work better on tumors in some organs than others. The study included 131 people with advanced liver cancer who had not received prior treatment. The goal was to understand which tumors respond best to this therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cha Medical Center
Seongnam-si, Gyeonggi-do, 13496, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
- Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
- New drug zanzalintinib tested for advanced liver cancer
- New drug cocktail shows promise for tough liver cancer
- Promising drug cocktail targets Hard-to-Treat liver cancer
- Virus therapy takes on liver cancer in major trial